2017
DOI: 10.1038/nm.4420
|View full text |Cite
|
Sign up to set email alerts
|

A microRNA screen reveals that elevated hepatic ectodysplasin A expression contributes to obesity-induced insulin resistance in skeletal muscle

Abstract: Over 40% of microRNAs (miRNAs) are located in introns of protein-coding genes, and many of these intronic miRNAs are co-regulated with their host genes. In such cases of co-regulation, the products of host genes and their intronic miRNAs can cooperate to coordinately regulate biologically important pathways. Therefore, we screened intronic miRNAs dysregulated in the livers of mouse models of obesity to identify previously uncharacterized protein-coding host genes that may contribute to the pathogenesis of obes… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
54
1
1

Year Published

2018
2018
2020
2020

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 55 publications
(59 citation statements)
references
References 56 publications
3
54
1
1
Order By: Relevance
“…Furthermore, hepatic ectodysplasin A (EDA), together with its intronic miRNA, miR-676, was upregulated and released from hepatocytes under conditions of obesity and could act on SM as its main target tissue; its increased expression in liver occurs due to a systemic IR. The probable mechanism was that EDA-A2 could enhance c-Jun N-terminal kinase (JNK) phosphorylation and inhibit phosphorylation of Ser307 of IRS-1 in vivo to cause obesity-induced IR [32]. Overexpression of miR-16 has been reported to inhibit the synthesis of insulin-stimulated SM protein, while several other miRNAs involved in muscle metabolism may be responsive to IR, including miR-149, -182, and -696, deserving further investigation [33].…”
Section: Ir and Mirnasmentioning
confidence: 99%
“…Furthermore, hepatic ectodysplasin A (EDA), together with its intronic miRNA, miR-676, was upregulated and released from hepatocytes under conditions of obesity and could act on SM as its main target tissue; its increased expression in liver occurs due to a systemic IR. The probable mechanism was that EDA-A2 could enhance c-Jun N-terminal kinase (JNK) phosphorylation and inhibit phosphorylation of Ser307 of IRS-1 in vivo to cause obesity-induced IR [32]. Overexpression of miR-16 has been reported to inhibit the synthesis of insulin-stimulated SM protein, while several other miRNAs involved in muscle metabolism may be responsive to IR, including miR-149, -182, and -696, deserving further investigation [33].…”
Section: Ir and Mirnasmentioning
confidence: 99%
“…At the present stage the purpose of drug developments is only or mainly to decrease the level of blood glucose or prevent elevation of blood glucose level. An increase in the blood glucose level is not the essential pathogenesis of type 2 diabetes mellitus, but only a result from occurrence of insulin resistance in type 2 diabetes mellitus [ 69 , 70 ]. For example, sulfonylurea stimulates insulin release from pancreatic β cells; biguanide blocks production of glucose from lactate mainly in the liver; glucosidase inhibitors diminish production of glucose by inhibiting glucosidases involved in breaking down of carbohydrates mainly in the intestine; thiazolidine stimulates glucose uptake via stimulation of adiponectin release from adipocytes by acting peroxisome proliferator-activated receptor (PPAR); dipeptidyl-peptidase IV (DPP-4) inhibitors maintain a high level of insulin by blocking brake-down of incretin in the intestine stimulating insulin release from pancreatic β cells; sodium-glucose cotransporter 2 (SGLT2) inhibitors diminish reuptake of glucose in the renal epithelia.…”
Section: Introductionmentioning
confidence: 99%
“…1 ug of total RNA per sample was used for library construction, and sequencing was performed in the Cologne Center for Genomics. Detailed methods were described previously 74 .…”
Section: Methodsmentioning
confidence: 99%